Page 1

Exhibit 99.1 CRONOS GROUP Cronos Group Reports 2021 Second Quarter Results Amended agreement with Ginkgo Bioworks to accelerate commercialization of cultured cannabinoids Announced strategic investment in PharmaCann , a leading U.S. cannabis company Spinach TM launched new products in the edible , concentrate , and flower categories in Canada TORONTO , August 6 , 2021 - Cronos Group Inc. ( NASDAQ : CRON ) ( TSX : CRON ) ( " Cronos Group " or the " Company " ) , today announces its 2021 Second Quarter business results . " This quarter , Cronos Group continued to bring high - quality and insight - driven products to market . I am particularly proud of the Spinach ™ brand gummy innovation launched this quarter into the Canadian adult - use market , SOURZ by Spinach TM , which has quickly jumped to be one of the most desirable products in the edibles category . In the U.S. , we officially re - launched PEACE + TM in the direct - to - consumer channel , which rounds out our different pricing tiers for the U.S. hemp - derived CBD market . Having brands across price points and usage occasions is critical to meeting consumer needs in the CBD category , " said Kurt Schmidt , President and CEO , Cronos Group . " Our U.S. growth strategy focuses on delivering long - term shareholder value by assembling a best - in - class brand and intellectual property portfolio and positioning to deploy our products in the U.S. market through investments and opportunities with companies that share our vision and commitment to responsibly distributing disruptive cannabinoid products that improve people's lives . In the second quarter of 2021 , we were able to lock in a component of that strategy as we made a strategic investment in PharmaCann , a leading vertically integrated U.S. cannabis company . We look forward to capitalizing on opportunities in the U.S. that we expect will strengthen our ability to compete in this emerging market . "